MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1.
Sign Up to like & getrecommendations! Published in 2019 at "Molecular medicine reports"
DOI: 10.3892/mmr.2018.9710
Abstract: Epidermal growth factor receptor‑tyrosine kinase inhibitors, such as gefitinib, have been found to be clinically effective in the treatment of patients with non‑small cell lung cancer (NSCLC). However, the therapeutic effect of gefitinib is often… read more here.
Keywords: gefitinib resistance; mir 506; 9gr cells; cell ... See more keywords